Results 81 to 90 of about 429,758 (251)

Hydroxyurea Treatment for Sickle Cell Disease

The Scientific World Journal, 2002
High fetal hemoglobin (HbF) levels inhibit the polymerization of sickle hemoglobin (HbS) and reduce the complications of sickle cell disease. Pharmacologic agents that can reverse the switch from γ- to β-chain synthesis — γ-globin chains characterize HbF,
Martin H. Steinberg
doaj   +1 more source

In Utero HSC Transplantation for Sickle Cell Disease: A Potential Therapeutic Approach That Overcomes Complications of Current Therapies

Prenatal Diagnosis, EarlyView.
ABSTRACT Sickle cell disease (SCD) affects millions worldwide but has limited treatment options, most of which carry significant side effects. At present, the only curative treatment for SCD is allogeneic or gene‐modified autologous hematopoietic stem cell (HSC) transplantation (Tx).
Oluwaseun O. Babatunde, Madeleine G. Bibby, Anthony Atala, Graça Almeida‐Porada, Christopher D. Porada   +4 more
wiley   +1 more source

A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.

New England Journal of Medicine, 2019
BACKGROUND Deoxygenated sickle hemoglobin (HbS) polymerization drives the pathophysiology of sickle cell disease. Therefore, direct inhibition of HbS polymerization has potential to favorably modify disease outcomes.
E. Vichinsky, C. Hoppe, K. Ataga, R. Ware, V. Nduba, A. El-Beshlawy, H. Hassab, Maureen M. Achebe, S. Alkindi, R. Brown, D. Diuguid, P. Telfer, Dimitris A. Tsitsikas, A. Elghandour, V. Gordeuk, J. Kanter, M. Abboud, J. Lehrer-Graiwer, M. Tonda, A. Intondi, B. Tong, J. Howard   +21 more
semanticscholar   +1 more source

Sickle Cell Disease: Historical Overview and Current Therapies

Prenatal Diagnosis, EarlyView.
ABSTRACT Sickle cell disease (SCD) affects millions worldwide, yet the limited treatment options currently available do not always adequately control the disease and carry significant side effects. At present, the only curative treatment is hematopoietic stem cell (HSC) transplantation, a procedure that carries considerable challenges and numerous ...
Oluwaseun O. Babatunde, Madeleine G. Bibby, Anthony Atala, Graça Almeida‐Porada, Christopher D. Porada   +4 more
wiley   +1 more source

Non‐Invasive Prenatal Diagnosis of Haemoglobinopathies: From Concept to Clinical Reality

Prenatal Diagnosis, EarlyView.
ABSTRACT Haemoglobinopathies are the most prevalent monogenic disorders worldwide, contributing significantly to childhood morbidity and mortality. Preventive strategies, including carrier screening and prenatal diagnosis, have successfully reduced disease incidence in regions with established programmes.
Irene Leonidou, Leila Sallie, Morgan Jean Bell‐Ricketts, Alexandros Abdel Massih, Lisa Joy Kaiser, Ashley Hoi Kiu Wong, María Teresa Martín Monreal, Panicos Shangaris   +7 more
wiley   +1 more source

Hemoglobinas variantes em doadores de sangue do Centro de Hematologia e Hemoterapia do estado do Piauí (Hemopi): conhecendo o perfil epidemiológico para construir a rede de assistência Hemoglobin S variants in blood donors of the Hematology and Hemotherapy Center of the state of Piauí (Hemopi): understanding the epidemiological profile to create a support network

Revista Brasileira de Hematologia e Hemoterapia, 2009
The most highly prevalent inherited disease in Brazil and in the world, sickle cell anemia, is considered a public health problem. Characterized by homozygosis for the hemoglobin S gene, the individual has a range of signs and symptoms that require ...
Leonardo F. Soares, Evaldo H. Oliveira, Iraildo B. Lima, José M. Silva, Jônathas T. Mota, Claudia R. Bonini-Domingos   +5 more
doaj   +1 more source

The Vaso-Occlusive Pain Crisis in Sickle Cell Disease: Definition, Pathophysiology, and Management.

European Journal of Haematology, 2020
Early diagnosis, treatment, and prevention of a vaso-occlusive crisis (VOC) is critical to the management of patients with sickle cell disease. It is essential to differentiate between VOC-associated pain and chronic pain, hyperalgesia, neuropathy, and ...
Deepika S. Darbari, V. Sheehan, S. Ballas   +2 more
semanticscholar   +1 more source

Long‐Term Outcomes After Elective Splenectomy for Haematological Disease: A 27‐Year Single‐Centre Study

ANZ Journal of Surgery, EarlyView.
Splenectomy is a safe and effective treatment option in selected patients with haematological disease, despite declining referrals over the last 27 years in the era of targeted therapies. Outcomes are favourable when performed laparoscopically and long‐term follow‐up demonstrates sustained haematologic benefit in surviving patients.
Salil Dutt Barrett, Anthony Downhill, Douglas Greer, William Stevenson, Ian Kerridge, Chris Ward, Matthew Greenwood, Naomi Mackinlay, Luke Coyle, Thomas J. Hugh   +9 more
wiley   +1 more source

Hemoglobin sickle cell disease in Brazil

Haematologica, 2012
We read with great interest the recent paper presented by Lionnet et al .[1][1] and we would like to briefly report our experience with hemoglobin SC (HbSC) disease. Before the institution of neonatal screening in Brazil, HbSC disease was considered a rare manifestation.[2][2] After 2001, however,
Ana Carolina Cabañas-Pedro, Josefina A. P. Braga, Roberta F Camilo-Araújo, Ana I. M. Silva, Perla Vicari, Maria Figueiredo   +5 more
openaire   +3 more sources

Maternal and perinatal outcomes associated with prophylactic erythrocytapheresis in pregnant women with sickle cell disease

International Journal of Gynecology &Obstetrics, EarlyView.
Pedro Junqueira Fleury Silva, Giovanna Santos Pinto Coelho, Luana de Jesus Pires, Camila Olivares Figueira, José Paulo de Siqueira Guida, Fernanda G. Surita, Juliana da‐Costa‐Santos, Bruno Deltreggia Benites, Paula de Melo Campos, Simone Cristina Olenscki Gilli, Sara T. O. Saad, Fernando F. Costa, Maria Laura Costa   +12 more
wiley   +1 more source